Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EPS (Weighted Average and Diluted) (2022 - 2026)

Centessa Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.48 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 47.25% to -$0.48 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.47 through Dec 2025, up 28.64% year-over-year, with the annual reading at -$1.46 for FY2025, 29.13% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.48 for Q4 2025 at Centessa Pharmaceuticals, down from -$0.41 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.2 in Q1 2025 and troughed at -$0.91 in Q4 2024.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.4 (2025), against an average of -$0.46.
  • Year-over-year, EPS (Weighted Average and Diluted) skyrocketed 62.32% in 2023 and then crashed 145.95% in 2024.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.45 in 2022, then increased by 17.78% to -$0.37 in 2023, then crashed by 145.95% to -$0.91 in 2024, then skyrocketed by 47.25% to -$0.48 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's EPS (Weighted Average and Diluted) are -$0.48 (Q4 2025), -$0.41 (Q3 2025), and -$0.38 (Q2 2025).